Commercialization of a proprietary GA-68 psma-targeted drug for pet imaging in recurrent prostate cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA233140
- Recipient
-
Five Eleven Pharma Inc. UEI PJUGJJT3FLM5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,400,935
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$0 | |
| Amendment | -$0 | |
| Amendment | $248,430 | |
| Amendment | $0 | |
| Amendment | $853,093 | |
| Original award | $299,412 |
Quick answers
Who received award R44CA233140?
R44CA233140 was awarded to Five Eleven Pharma Inc. by National Cancer Institute (National Institutes of Health) on August 10, 2018.
How much is award R44CA233140 worth?
$1,400,935 has been obligated on R44CA233140.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award